Pituitary tumorous hyperplasia due to primary hypothyroidism

Acta Neurochir (Wien). 2012 Aug;154(8):1489-92; discussion 1492. doi: 10.1007/s00701-012-1342-0. Epub 2012 Apr 17.

Abstract

Background: To study the diagnostic and therapeutic features of pituitary tumorous hyperplasia due to primary hypothyroidism.

Methods: Fifteen patients with pituitary tumorous hyperplasia were studied in clinical manifestation, pathologic, endocrinological, radiographic and therapeutic features retrospectively.

Results: All of these patients suffered from primary hypothyroidism. Magnetic resonance imaging (MRI) scanning found that there were masses in the sellar region with equal T1 and little longer T2 signal, and which could be obviously enhanced by gadolinium EDTA injection. Diameters of these masses were between 1.1 and 2.5 cm. Thyroxine substitution therapy was ordered. Four months later, MRI scanning found that the masses disappeared and only normal pituitary gland left. Plasma thyroxine, thyroid-stimulating hormone (TSH), and prolactin (PRL) levels dropped to their normal ranges.

Conclusions: Thyroxine substitution therapy was the first choice of pituitary tumorous hyperplasia due to primary hypothyroidism. If they are followed by TSH adenoma, or the optic chiasma was pressed by the enlarged pituitary, transsphenoidal microsurgery could be applied.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Female
  • Humans
  • Hyperplasia / drug therapy
  • Hyperplasia / etiology
  • Hypothyroidism / complications
  • Hypothyroidism / diagnosis
  • Hypothyroidism / drug therapy*
  • Hypothyroidism / pathology*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Pituitary Gland / pathology
  • Pituitary Neoplasms / diagnosis
  • Pituitary Neoplasms / drug therapy*
  • Pituitary Neoplasms / etiology
  • Pituitary Neoplasms / pathology*
  • Retrospective Studies
  • Thyroxine / blood
  • Thyroxine / therapeutic use*
  • Young Adult

Substances

  • Thyroxine